Polymorphism (materials science)

Ability of a solid material to exist in more than one form or crystal structure

In materials science, polymorphism describes the existence of a solid material in more than one form or crystal structure. Polymorphism is a form of isomerism. Any crystalline material can exhibit the phenomenon. Allotropy refers to polymorphism for chemical elements. Polymorphism is of practical relevance to pharmaceuticals, agrochemicals, pigments, dyestuffs, foods, and explosives. According to IUPAC, a polymorphic transition is "A reversible transition of a solid crystalline phase at a certain temperature and pressure (the inversion point) to another phase of the same chemical composition with a different crystal structure."[1] According to McCrone, polymorphs are "different in crystal structure but identical in the liquid or vapor states."[2][3] Materials with two polymorphs are called dimorphic, with three polymorphs, trimorphic, etc.[4]

In some cases, polymorphism was "discovered" on a computer by crystal structure prediction first, before chemists actually synthesize the crystal in the lab.[5]

## Examples[edit]

Many compounds exhibit polymorphism. It has been claimed that "every compound has different polymorphic forms, and that, in general, the number of forms known for a given compound is proportional to the time and money spent in research on that compound."[6][2][7]

### Organic compounds[edit]

Calcite (on left) and Aragonite (on right), two forms of calcium carbonate. Note: the colors are from impurities.

#### Benzamide[edit]

The phenomenon was discovered in 1832 by Friedrich Wöhler and Justus von Liebig. They observed that the silky needles of freshly crystallized benzamide slowly converted to rhombic crystals.[8] Present-day analysis[9] identifies three polymorphs for benzamide: the least stable one, formed by flash cooling is the orthorhombic form II. This type is followed by the monoclinic form III (observed by Wöhler/Liebig). The most stable form is monoclinic form I. The hydrogen bonding mechanisms are the same for all three phases; however, they differ strongly in their pi-pi interactions.

#### Maleic acid[edit]

In 2006 a new polymorph of maleic acid was discovered, 124 years after the first crystal form was studied.[10] Maleic acid is manufactured on an industrial scale in the chemical industry. It forms salt found in medicine. The new crystal type is produced when a co-crystal of caffeine and maleic acid (2:1) is dissolved in chloroform and when the solvent is allowed to evaporate slowly. Whereas form I has monoclinic space group P21/c, the new form has space group Pc. Both polymorphs consist of sheets of molecules connected through hydrogen bonding of the carboxylic acid groups: in form I, the sheets alternate with respect of the net dipole moment, while in form II, the sheets are oriented in the same direction.

#### 1,3,5-Trinitrobenzene[edit]

After 125 years of study, 1,3,5-trinitrobenzene yielded a second polymorph. The usual form has the space group Pbca, but in 2004, a second polymorph was obtained in the space group Pca21 when the compound was crystallised in the presence of an additive, trisindane. This experiment shows that additives can induce the appearance of polymorphic forms.[11]

#### Other organic compounds[edit]

Acridine has been obtained as eight polymorphs[12] and aripiprazole has nine.[13] The record for the largest number of well-characterised polymorphs is held by a compound known as ROY.[14][15] Glycine crystallizes as both monoclinic and hexagonal crystals. Polymorphism in organic compounds is often the result of conformational polymorphism.[16]

### Inorganic compounds[edit]

#### Binary metal oxides[edit]

Polymorphism in binary metal oxides has attracted much attention because these materials are of significant economic value. One set of famous examples have the composition SiO2, which form many polymorphs. Important ones include: α-quartz, β-quartz, tridymite, cristobalite, moganite, coesite, and stishovite.[17] [18]

Metal oxides | Phase | Conditions of P and T | Structure/Space Group

|
|
|

CrO2 | α phase | Ambient conditionsCl2-type Orthorhombic
RT and 12±3 GPa
Cr2O3 | Corundum phase | Ambient conditions | Corundum-type Rhombohedral (R3c)
High pressure phase | RT and 35 GPa | Rh2O3-II type
Fe2O3 | α phase | Ambient conditions | Corundum-type Rhombohedral (R3c)
β phase | Below 773 K | Body-centered cubic (Ia3)
γ phase | Up to 933 K | Cubic spinel structure (Fd3m)
ε phase | \-- | Rhombic (Pna21)
Bi2O3 | α phase | Ambient conditions | Monoclinic (P21/c)
β phase | 603-923 K and 1 atm | Tetragonal
γ phase | 773-912 K or RT and 1 atm | Body-centered cubic
δ phase | 912-1097 K and 1 atm | FCC (Fm3m)
In2O3 | Bixbyite-type phase | Ambient conditions | Cubic (Ia3)
Corundum-type | 15-25 GPa at 1273 K | Corundum-type Hexagonal (R3c)
Rh2O3(II)-type | 100 GPa and 1000 K | Orthorhombic
Al2O3 | α phase | Ambient conditions | Corundum-type Trigonal (R3c)
γ phase | 773 K and 1 atm | Cubic (Fd3m)
SnO2 | α phase | Ambient conditions | Rutile-type Tetragonal (P42/mnm)
CaCl2-type phase | 15 KBar at 1073 K | Orthorhombic, CaCl2-type (Pnnm)
α-PbO2-type | Above 18 KBar | α-PbO2-type (Pbcn)
TiO2 | Rutile | Equilibrium phase | Rutile-type Tetragonal
Anatase | Metastable phase (Not stable)[19] | Tetragonal (I41/amd)
Brookite | Metastable phase (Not stable)[19] | Orthorhombic (Pcab)
ZrO2 | Monoclinic phase | Ambient conditions | Monoclinic (P21/c)
Tetragonal phase | Above 1443 K | Tetragonal (P42/nmc)
Fluorite-type phase | Above 2643 K | Cubic (Fm3m)
MoO3 | α phase | 553-673 K & 1 atm | Orthorhombic (Pbnm)
β phase | 553-673 K & 1 atm | Monoclinic
h phase | High-pressure and high-temperature phase | Hexagonal (P6a/m or P6a)
MoO3-II | 60 kbar and 973 K | Monoclinic
WO3 | ε phase | Up to 220 K | Monoclinic (Pc)
δ phase | 220-300 K | Triclinic (P1)
γ phase | 300-623 K | Monoclinic (P21/n)
β phase | 623-900 K | Orthorhombic (Pnma)
α phase | Above 900 K | Tetragonal (P4/ncc)

#### Other inorganic materials[edit]

Classical examples of polymorphism are the pair of minerals calcite and aragonite, both forms of calcium carbonate. Perhaps the most famous example is that of the polymorphs of carbon: graphite and diamond.

β-HgS precipitates as a black solid when Hg(II) salts are treated with H2S. With gentle heating of the slurry, the black polymorph converts to the red form.[20]

## Factors affecting polymorphism[edit]

According to Ostwald's rule, usually less stable polymorphs crystallize before the stable form. The concept hinges on the idea that unstable polymorphs more closely resemble the state in solution, and thus are kinetically advantaged. The founding case of fibrous vs rhombic benzamide illustrates the case. Another example is provided by two polymorphs of titanium dioxide.[19] Nevertheless, there are known systems, such as metacetamol, where only narrow cooling rate favors obtaining metastable form II.[21]

Polymorphs have disparate stabilities. Some convert rapidly at room (or any) temperature. Most polymorphs of organic molecules only differ by a few kJ/mol in lattice energy. Approximately 50% of known polymorph pairs differ by less than 2 kJ/mol and stability differences of more than 10 kJ/mol are rare.[22] Valuable to mention that polymorph stability may change upon temperature[23][24][25] or pressure.[26][27] Important to note that structural and thermodybnamic stability are different. Thermodynamic stability may be studied using experimental or computational methods.[28][29]

Polymorphism is affected by the details of crystallisation. The solvent in all respects affects the nature of the polymorph, including concentration, other components of the solvent, i.e., species that inhibiting or promote certain growth patterns.[30] A decisive factor is often the temperature of the solvent from which crystallisation is carried out.[31]

Metastable polymorphs are not always reproducibly obtained, leading to cases of "disappearing polymorphs", with usually negative implications on law and business.[6][5][32]

## In pharmaceuticals[edit]

Main article: Disappearing polymorphs

### Legal aspects[edit]

Drugs receive regulatory approval and are granted patents for only a single polymorph.

In a classic patent dispute, the GlaxoSmithKline defended its patent for the Type II polymorph of the active ingredient in Zantac against competitors while that of the Type I polymorph had already expired.[33]

Polymorphism in drugs can also have direct medical implications since dissolution rates depend on the polymorph. Polymorphic purity of drug samples can be checked using techniques such as powder X-ray diffraction, IR/Raman spectroscopy, and utilizing the differences in their optical properties in some cases.[34]

### Case studies[edit]

The known cases up to 2015 are discussed in a review article by Bučar, Lancaster, and Bernstein.[5]

Dibenzoxazepines

Multidisciplinary studies involving experimental and computational approaches were applied to pharmaceutical molecules to facilitate the comparison of their solid-state structures. Specifically, this study has focused on exploring how changes in molecular structure affect the molecular conformation, packing motifs, interactions in the resultant crystal lattices and the extent of solid-state diversity of these compounds. The results highlight the value of crystal structure prediction studies and PIXEL calculations in the interpretation of the observed solid-state behaviour and quantifying the intermolecular interactions in the packed structures and identifying the key stabilising interactions. An experimental screen yielded 4 physical forms for clozapine as compared to 60 distinct physical forms for olanzapine. The experimental screening results of clozapine are consistent with its crystal energy landscape which confirms that no alternate packing arrangement is thermodynamically competitive to the experimentally obtained structure. Whilst in case of olanzapine, crystal energy landscape highlights that the extensive experimental screening has probably not found all possible polymorphs of olanzapine, and further solid form diversity could be targeted with a better understanding of the role of kinetics in its crystallisation. CSP studies were able to offer an explanation for the absence of the centrosymmetric dimer in anhydrous clozapine. PIXEL calculations on all the crystal structures of clozapine revealed that similar to olanzapine, the intermolecular interaction energy in each structure is also dominated by the Ed. Despite the molecular structure similarity between amoxapine and loxapine (molecules in group 2), the crystal packing observed in polymorphs of loxa differs significantly from the amoxapine. A combined experimental and computational study demonstrated that the methyl group in loxapine has a significant influence in increasing the range of accessible solid forms and favouring various alternate packing arrangements. CSP studies have again helped in explaining the observed solid-state diversity of loxapine and amoxapine. PIXEL calculations showed that in absence of strong H-bonds, weak H-bonds such as C–H...O, C–H...N and dispersion interactions play a key role in stabilising the crystal lattice of both the molecules. Efficient crystal packing of amoxapine seems to be contributing towards its monomorphic behaviour as compared to the comparatively less efficient packing of loxapine molecules in both polymorphs. The combination of experimental and computational approaches has provided a deeper understanding of the factors influencing the solid-state structure and diversity in these compounds. Hirshfeld surfaces using Crystal Explorer represent another way of exploring packing modes and intermolecular interactions in molecular crystals. The influence of changes in the small substituents on shape and electron distribution can also be investigated by mapping the total electron density on the electrostatic potential for molecules in the gas phase. This allows straightforward visualisation and comparison of overall shape, electron-rich and electron-deficient regions within molecules. The shape of these molecules can be further investigated to study its influence on diverse solid-state diversity.[35]

Posaconazole

The original formulations of posaconazole on the market licensed as Noxafil(R) were formulated utilising form I of posaconazole. The discovery of polymorphs of posaconazole increased rapidly and resulted in much research in crystallography of posaconazole. A methanol solvate and a 1,4-dioxane co-crystal were added to the Cambridge Structural Database (CSD).[36]

#### Ritonavir[edit]

The antiviral drug ritonavir exists as two polymorphs, which differ greatly in efficacy. Such issues were solved by reformulating the medicine into gelcaps and tablets, rather than the original capsules.[37]

#### Aspirin[edit]

There was only one proven polymorph Form I of aspirin, though the existence of another polymorph was debated since the 1960s, and one report from 1981 reported that when crystallized in the presence of aspirin anhydride, the diffractogram of aspirin has weak additional peaks. Though at the time it was dismissed as mere impurity, it was, in retrospect, Form II aspirin.[5]

Form II was reported in 2005,[38][39] found after attempted co-crystallization of aspirin and levetiracetam from hot acetonitrile.

In form I, pairs of aspirin molecules form centrosymmetric dimers through the acetyl groups with the (acidic) methyl proton to carbonyl hydrogen bonds. In form II, each aspirin molecule forms the same hydrogen bonds, but with two neighbouring molecules instead of one. With respect to the hydrogen bonds formed by the carboxylic acid groups, both polymorphs form identical dimer structures. The aspirin polymorphs contain identical 2-dimensional sections and are therefore more precisely described as polytypes.[40]

Pure Form II aspirin could be prepared by seeding the batch with aspirin anhydrate in 15% weight.[5]

#### Paracetamol[edit]

Paracetamol powder has poor compression properties, which poses difficulty in making tablets. A second polymorph was found with more suitable compressive properties.[41]

#### Cortisone acetate[edit]

Cortisone acetate exists in at least five different polymorphs, four of which are unstable in water and change to a stable form.

#### Carbamazepine[edit]

Carbamazepine, estrogen, paroxetine,[42] and chloramphenicol also show polymorphism.

#### Pyrazinamide[edit]

Pyrazinamide has at least 4 polymorphs.[43] All of them transforms to stable α form at room temperature upon storage or mechanical treatment.[44] Recent studies prove that α form is thermodynamically stable at room temperature.[23][25]

## Polytypism[edit]

Polytypes are a special case of polymorphs, where multiple close-packed crystal structures differ in one dimension only. Polytypes have identical close-packed planes, but differ in the stacking sequence in the third dimension perpendicular to these planes. Silicon carbide (SiC) has more than 170 known polytypes, although most are rare. All the polytypes of SiC have virtually the same density and Gibbs free energy. The most common SiC polytypes are shown in Table 1.

Table 1: Some polytypes of SiC.[45]

Phase | Structure | Ramsdell notation | Stacking sequence | Comment

|
|
|
|

α-SiC  | hexagonal  | 2H  | AB  | wurtzite form
α-SiC  | hexagonal  | 4H  | ABCB  |
α-SiC  | hexagonal  | 6H  | ABCACB  | the most stable and common form
α-SiC  | rhombohedral  | 15R  | ABCACBCABACABCB  |
β-SiC  | face-centered cubic | 3C  | ABC  | sphalerite or zinc blende form

A second group of materials with different polytypes are the transition metal dichalcogenides, layered materials such as molybdenum disulfide (MoS2). For these materials the polytypes have more distinct effects on material properties, e.g. for MoS2, the 1T polytype is metallic in character, while the 2H form is more semiconducting.[46] Another example is tantalum disulfide, where the common 1T as well as 2H polytypes occur, but also more complex 'mixed coordination' types such as 4Hb and 6R, where the trigonal prismatic and the octahedral geometry layers are mixed.[47] Here, the 1T polytype exhibits a charge density wave, with distinct influence on the conductivity as a function of temperature, while the 2H polytype exhibits superconductivity.

ZnS and CdI2 are also polytypical.[48] It has been suggested that this type of polymorphism is due to kinetics where screw dislocations rapidly reproduce partly disordered sequences in a periodic fashion.

## Theory[edit]

Solid phase transitions which transform reversibly without passing through the liquid or gaseous phases are called enantiotropic. In contrast, if the modifications are not convertible under these conditions, the system is monotropic. Experimental data are used to differentiate between enantiotropic and monotropic transitions and energy/temperature semi-quantitative diagrams can be drawn by applying several rules, principally the heat-of-transition rule, the heat-of-fusion rule and the density rule. These rules enable the deduction of the relative positions of the H and Gisobars in the E/T diagram. [1]

In terms of thermodynamics, two types of polymorphic behaviour are recognized. For a monotropic system, plots of the free energies of the various polymorphs against temperature do not cross before all polymorphs melt. As a result, any transition from one polymorph to another below the melting point will be irreversible. For an enantiotropic system, a plot of the free energy against temperature shows a crossing point before the various melting points.[49] It may also be possible to convert interchangeably between the two polymorphs by heating or cooling, or through physical contact with a lower energy polymorph.

A simple model of polymorphism is to model the Gibbs free energy of a ball-shaped crystal as  G = a r 2 − b r 3 {\displaystyle G=ar^{2}-br^{3}} . Here, the first term  a r 2 {\displaystyle ar^{2}} is the surface energy, and the second term  − b r 3 {\displaystyle -br^{3}} is the volume energy. Both parameters  a , b > 0 {\displaystyle a,b>0} . The function  G ( r ) {\displaystyle G(r)} rises to a maximum before dropping, crossing zero at  r c r i t {\displaystyle r_{crit}} . In order to crystallize, a ball of crystal much overcome the energetic barrier to the  r > r c r i t {\displaystyle r>r_{crit}} part of the energy landscape.[50]

Figure 2

Now, suppose there are two kinds of crystals, with different energies  G 1 = a 1 r 2 − b 1 r 3 {\displaystyle G_{1}=a_{1}r^{2}-b_{1}r^{3}} and  G 2 = a 2 r 2 − b 2 r 3 {\displaystyle G_{2}=a_{2}r^{2}-b_{2}r^{3}} , and if they have the same shape as in Figure 2, then the two curves intersect at some  r c r i t ′ > r c r i t , 1 {\displaystyle r'_{crit}>r_{crit,1}} . Then the system has three phases:

* r < r c r i t , 1 {\displaystyle r<r_{crit,1}} . Crystals tend to dissolve. Amorphous phase.
* r c r i t , 1 < r < r c r i t ′ {\displaystyle r_{crit,1}<r<r'_{crit}} . Crystals tend to grow as form 1.
* r > r c r i t ′ {\displaystyle r>r'_{crit}} . Crystals tend to grow as form 2.

If the crystal is grown slowly, it could be kinetically stuck in form 1.

## See also[edit]

Wikimedia Commons has media related to Polymorphism.

* Isomorphism (crystallography)
* Dimorphism (Wiktionary)
* Polyamorphism

## References[edit]

1. ^ "Polymorphic transition". Polymorphicc transition. 2009. doi:10.1351/goldbook.P04748. ISBN 978-0-9678550-9-7. `{{cite book}}`: `|website=` ignored (help)
2. ^ a b McCrone, W. C. (1965). "Polymorphism". In Fox, D.; Labes, M.; Weissberger, A. (eds.). Physics and Chemistry of the Organic Solid State. Vol. 2\. Wiley-Interscience. pp. 726–767.
3. ^ Dunitz, Jack D.; Bernstein, Joel (1995-04-01). "Disappearing Polymorphs". Accounts of Chemical Research. 28 (4): 193–200. doi:10.1021/ar00052a005. ISSN 0001-4842.
4. ^ "Definition of trimorphism - mindat.org glossary". www.mindat.org. Retrieved 2016-10-23.
5. ^ a b c d e Bučar, D.-K.; Lancaster, R. W.; Bernstein, J. (2015). "Disappearing Polymorphs Revisited". Angewandte Chemie International Edition. 54 (24): 6972–6993. doi:10.1002/anie.201410356. PMC 4479028. PMID 26031248.
6. ^ a b Crystal Engineering: The Design and Application of Functional Solids, Volume 539, Kenneth Richard Seddon, Michael Zaworotk 1999
7. ^ Pharmaceutical Stress Testing: Predicting Drug Degradation, Second Edition Steven W. Baertschi, Karen M. Alsante, Robert A. Reed 2011 CRC Press
8. ^ Wöhler, F.; Liebig, J.; Ann (1832). "Untersuchungen über das Radikal der Benzoesäure". Annalen der Pharmacie (in German). Wiley. 3 (3): 249–282. doi:10.1002/jlac.18320030302. hdl:2027/hvd.hxdg3f. ISSN 0365-5490.
9. ^ Thun, Jürgen (2007). "Polymorphism in Benzamide: Solving a 175-Year-Old Riddle". Angewandte Chemie International Edition. 46 (35): 6729–6731. doi:10.1002/anie.200701383. PMID 17665385.
10. ^ Graeme M. Day; Andrew V. Trask; W. D. Samuel Motherwell; William Jones (2006). "Investigating the Latent Polymorphism of Maleic Acid". Chemical Communications. 1 (1): 54–56. doi:10.1039/b513442k. PMID 16353090.
11. ^ Thallapally PK, Jetti RK, Katz AK (2004). "Polymorphism of 1,3,5-trinitrobenzene Induced by a Trisindane Additive". Angewandte Chemie International Edition. 43 (9): 1149–1155. doi:10.1002/anie.200352253. PMID 14983460.
12. ^ Schur, Einat; Bernstein, Joel; Price, Louise S.; Guo, Rui; Price, Sarah L.; Lapidus, Saul H.; Stephens, Peter W. (2019). "The (Current) Acridine Solid Form Landscape: Eight Polymorphs and a Hydrate" (PDF). Crystal Growth & Design. 19 (8): 4884–4893. doi:10.1021/acs.cgd.9b00557. S2CID 198349955.
13. ^ Serezhkin, Viktor N.; Savchenkov, Anton V. (2020). "Application of the Method of Molecular Voronoi–Dirichlet Polyhedra for Analysis of Noncovalent Interactions in Aripiprazole Polymorphs". Crystal Growth & Design. 20 (3): 1997–2003. doi:10.1021/acs.cgd.9b01645. S2CID 213824513.
14. ^ Krämer, Katrina (2020-07-29). "Red–orange–yellow reclaims polymorph record with help from molecular cousin". chemistryworld.com. Retrieved 2021-05-07.
15. ^ Tyler, Andrew R.; Ragbirsingh, Ronnie; McMonagle, Charles J.; Waddell, Paul G.; Heaps, Sarah E.; Steed, Jonathan W.; Thaw, Paul; Hall, Michael J.; Probert, Michael R. (2020). "Encapsulated Nanodroplet Crystallization of Organic-Soluble Small Molecules". Chem. 6 (7): 1755–1765. doi:10.1016/j.chempr.2020.04.009. PMC 7357602. PMID 32685768.
16. ^ Cruz-Cabeza, Aurora J.; Bernstein, Joel (2014). "Conformational Polymorphism". Chemical Reviews. 114 (4): 2170–2191. doi:10.1021/cr400249d. PMID 24350653.
17. ^ "Definition of polymorphism - mindat.org glossary". www.mindat.org. Retrieved 2016-10-23.
18. ^ "Polymorphism in nanocrystalline binary metal oxides", S. Sood, P.Gouma, Nanomaterials and Energy, 2(NME2), 1-15(2013).
19. ^ a b c Anatase to Rutile Transformation(ART) summarized in the Journal of Materials Science 2011
20. ^ Newell, Lyman C.; Maxson, R. N.; Filson, M. H. (1939). "Red Mercuric Sulfide". Inorganic Syntheses. Vol. 1\. pp. 19–20. doi:10.1002/9780470132326.ch7. ISBN 9780470132326.
21. ^ Drebushchak, V. A.; McGregor, L.; Rychkov, D. A. (February 2017). "Cooling rate "window" in the crystallization of metacetamol form II". Journal of Thermal Analysis and Calorimetry. 127 (2): 1807–1814. doi:10.1007/s10973-016-5954-0. ISSN 1388-6150. S2CID 99391719.
22. ^ Nyman, Jonas; Day, Graeme M. (2015). "Static and lattice vibrational energy differences between polymorphs". CrystEngComm. 17 (28): 5154–5165. doi:10.1039/C5CE00045A.
23. ^ a b Dubok, Aleksandr S.; Rychkov, Denis A. (2023-04-04). "Relative Stability of Pyrazinamide Polymorphs Revisited: A Computational Study of Bending and Brittle Forms Phase Transitions in a Broad Temperature Range". Crystals. 13 (4): 617. doi:10.3390/cryst13040617. ISSN 2073-4352.
24. ^ Borba, Ana; Albrecht, Merwe; Gómez-Zavaglia, Andrea; Suhm, Martin A.; Fausto, Rui (2010-01-14). "Low Temperature Infrared Spectroscopy Study of Pyrazinamide: From the Isolated Monomer to the Stable Low Temperature Crystalline Phase". The Journal of Physical Chemistry A. 114 (1): 151–161. doi:10.1021/jp907466h. hdl:11336/131247. ISSN 1089-5639. PMID 20055514.
25. ^ a b Hoser, Anna Agnieszka; Rekis, Toms; Madsen, Anders Østergaard (2022-06-01). "Dynamics and disorder: on the stability of pyrazinamide polymorphs". Acta Crystallographica Section B Structural Science, Crystal Engineering and Materials. 78 (3): 416–424. doi:10.1107/S2052520622004577. ISSN 2052-5206. PMC 9254588. PMID 35695115.
26. ^ Smirnova, Valeriya Yu.; Iurchenkova, Anna A.; Rychkov, Denis A. (2022-08-17). "Computational Investigation of the Stability of Di-p-Tolyl Disulfide "Hidden" and "Conventional" Polymorphs at High Pressures". Crystals. 12 (8): 1157. doi:10.3390/cryst12081157. ISSN 2073-4352.
27. ^ Rychkov, Denis A.; Stare, Jernej; Boldyreva, Elena V. (2017). "Pressure-driven phase transition mechanisms revealed by quantum chemistry: l -serine polymorphs". Physical Chemistry Chemical Physics. 19 (9): 6671–6676. doi:10.1039/C6CP07721H. ISSN 1463-9076. PMID 28210731.
28. ^ Rychkov, Denis A. (2020-01-31). "A Short Review of Current Computational Concepts for High-Pressure Phase Transition Studies in Molecular Crystals". Crystals. 10 (2): 81. doi:10.3390/cryst10020081. ISSN 2073-4352.
29. ^ Fedorov, A. Yu.; Rychkov, D. A. (September 2020). "Comparison of Different Computational Approaches for Unveiling the High-Pressure Behavior of Organic Crystals at a Molecular Level. Case Study of Tolazamide Polymorphs". Journal of Structural Chemistry. 61 (9): 1356–1366. doi:10.1134/S0022476620090024. ISSN 0022-4766. S2CID 222299340.
30. ^ Rychkov, Denis A.; Arkhipov, Sergey G.; Boldyreva, Elena V. (2014-08-01). "Simple and efficient modifications of well known techniques for reliable growth of high-quality crystals of small bioorganic molecules". Journal of Applied Crystallography. 47 (4): 1435–1442. doi:10.1107/S1600576714011273. ISSN 1600-5767.
31. ^ Buckley, Harold Eugene (1951). Crystal Growth. Wiley.
32. ^ Surov, Artem O.; Vasilev, Nikita A.; Churakov, Andrei V.; Stroh, Julia; Emmerling, Franziska; Perlovich, German L. (2019). "Solid Forms of Ciprofloxacin Salicylate: Polymorphism, Formation Pathways and Thermodynamic Stability". Crystal Growth & Design. 19 (5): 2979–2990. doi:10.1021/acs.cgd.9b00185. S2CID 132854494.
33. ^ "Accredited Degree Programmes" (PDF).
34. ^ Thomas, Sajesh P.; Nagarajan, K.; Row, T. N. Guru (2012). "Polymorphism and tautomeric preference in fenobam and the utility of NLO response to detect polymorphic impurities". Chemical Communications. 48 (85): 10559–10561. doi:10.1039/C2CC34912D. PMID 23000909.
35. ^ Bhardwaj, Rajni M. (2016), "Exploring the Physical Form Landscape of Clozapine, Amoxapine and Loxapine", Control and Prediction of Solid-State of Pharmaceuticals, Cham: Springer International Publishing, pp. 153–193, doi:10.1007/978-3-319-27555-0_7, ISBN 978-3-319-27554-3, retrieved 2023-12-20
36. ^ McQuiston, Dylan K.; Mucalo, Michael R.; Saunders, Graham C. (2019-03-05). "The structure of posaconazole and its solvates with methanol, and dioxane and water: Difluorophenyl as a hydrogen bond donor". Journal of Molecular Structure. 1179: 477–486. doi:10.1016/j.molstruc.2018.11.031. ISSN 0022-2860.
37. ^ Bauer J, et al. (2004). "Ritonavir: An Extraordinary Example of Conformational Polymorphism". Pharmaceutical Research. 18 (6): 859–866. doi:10.1023/A:1011052932607. PMID 11474792. S2CID 20923508.
38. ^ Peddy Vishweshwar; Jennifer A. McMahon; Mark Oliveira; Matthew L. Peterson & Michael J. Zaworotko (2005). "The Predictably Elusive Form II of Aspirin". J. Am. Chem. Soc. 127 (48): 16802–16803. doi:10.1021/ja056455b. PMID 16316223.
39. ^ Andrew D. Bond; Roland Boese; Gautam R. Desiraju (2007). "On the Polymorphism of Aspirin: Crystalline Aspirin as Intergrowths of Two "Polymorphic" Domains". Angewandte Chemie International Edition. 46 (4): 618–622. doi:10.1002/anie.200603373. PMID 17139692.
40. ^ "Polytypism - Online Dictionary of Crystallography". reference.iucr.org.
41. ^ Wang, In-Chun; Lee, Min-Jeong; Seo, Da-Young; Lee, Hea-Eun; Choi, Yongsun; Kim, Woo-Sik; Kim, Chang-Sam; Jeong, Myung-Yung; Choi, Guang Jin (14 June 2011). "Polymorph Transformation in Paracetamol Monitored by In-line NIR Spectroscopy During a Cooling Crystallization Process". AAPS PharmSciTech. 12 (2): 764–770. doi:10.1208/s12249-011-9642-x. PMC 3134639. PMID 21671200.
42. ^ "Disappearing Polymorphs and Gastrointestinal Infringement". blakes.com. 20 July 2012. Archived from the original on 20 July 2012.
43. ^ Castro, Ricardo A. E.; Maria, Teresa M. R.; Évora, António O. L.; Feiteira, Joana C.; Silva, M. Ramos; Beja, A. Matos; Canotilho, João; Eusébio, M. Ermelinda S. (2010-01-06). "A New Insight into Pyrazinamide Polymorphic Forms and their Thermodynamic Relationships". Crystal Growth & Design. 10 (1): 274–282. doi:10.1021/cg900890n. ISSN 1528-7483.
44. ^ Cherukuvada, Suryanarayan; Thakuria, Ranjit; Nangia, Ashwini (2010-09-01). "Pyrazinamide Polymorphs: Relative Stability and Vibrational Spectroscopy". Crystal Growth & Design. 10 (9): 3931–3941. doi:10.1021/cg1004424. ISSN 1528-7483.
45. ^ "The basics of crystallography and diffraction", Christopher Hammond, Second edition, Oxford science publishers, IUCr, page 28 ISBN 0 19 8505531.
46. ^ Li, Xiao; Zhu, Hongwei (2015-03-01). "Two-dimensional MoS2: Properties, preparation, and applications". Journal of Materiomics. 1 (1): 33–44. doi:10.1016/j.jmat.2015.03.003.
47. ^ Wilson, J.A.; Di Salvo, F. J.; Mahajan, S. (October 1974). "Charge-density waves and superlattices in the metallic layered transition metal dichalcogenides". Advances in Physics. 50 (8): 1171–1248. doi:10.1080/00018730110102718. S2CID 218647397.
48. ^ C.E. Ryan, R.C. Marshall, J.J. Hawley, I. Berman & D.P. Considine, "The Conversion of Cubic to Hexagonal Silicon Carbide as a Function of Temperature and Pressure," U.S. Air Force, Physical Sciences Research Papers, #336, Aug 1967, p 1-26.
49. ^ Carletta, Andrea (2015). "Solid-State Investigation of Polymorphism and Tautomerism of Phenylthiazole-thione: A Combined Crystallographic, Calorimetric, and Theoretical Survey". Crystal Growth & Design. 15 (5): 2461–2473. doi:10.1021/acs.cgd.5b00237.
50. ^ Ward, Michael D. (February 2017). "Perils of Polymorphism: Size Matters". Israel Journal of Chemistry. 57 (1–2): 82–92. doi:10.1002/ijch.201600071. ISSN 0021-2148.

## External links[edit]

* "Small Molecule Crystallization" (PDF) at Illinois Institute of Technology website
* "SiC and Polytpism"

Authority control databases: National |

* France
* BnF data
* Germany
* Israel
* United States

|